BACTI B Share Price Performance
SEK 17.30
-20.70 (-54.47%)
55.4% undervalued intrinsic discount
SEK 38.75
Fair Value
Price SEK 17.30
AnalystConsensusTarget SEK 38.75
Fair ValueSEK 38.75
Share Pricen/a
Bactiguard Holding AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
BACTI B Community Narratives
AN
Fair Value SEK 38.75 55.4% undervalued intrinsic discount
Infection Prevention Demand Will Drive Licensing Revenue And Margin Expansion Over The Coming Years
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Infection Prevention Demand Will Drive Licensing Revenue And Margin Expansion Over The Coming Years
Catalysts About Bactiguard Holding Bactiguard Holding develops and licenses infection prevention coating technology and wound management solutions for global MedTech partners. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
SEK 38.75
55.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
12.23% p.a.
Profit Margin
15.38%
Future PE
34.42x
Price in 2028
SEK 46.51
Trending Discussion
Recently Updated Narratives
AN
Infection Prevention Demand Will Drive Licensing Revenue And Margin Expansion Over The Coming Years
Fair Value: SEK 38.75 55.4% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Bactiguard Holding AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 05, 2026
- -0.61
- 86.36%
- -9.77%
- 39.9%
About BACTI B
- Founded
- 2005
- Employees
- 157
- CEO
- WebsiteView website
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for improved wound healing; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures. It operates in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. The company has licensed partnership with Becton, Dickinson & Company for urinary catheter bardex IC and lubrisil IC; Well Lead Medical for catheters and tubes; and Zimmer Biomet for orthopedic trauma implants. The company was founded in 2005 and is headquartered in Stockholm, Sweden.
